PACANALOTAMAB
UNII 102VUR9WQE

Substance Identification & Data

This profile provides standardized clinical and technical data for Pacanalotamab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 102VUR9WQE.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2251756-52-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

102VUR9WQE

CAS Registry Number

2251756-52-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PACANALOTAMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C159652

National Cancer Institute reference terminology for clinical and research data.

INN ID

11289

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

HI-216

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Pacanalotamab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

PACANALOTAMAB

Common Names & Synonyms

BISPECIFIC T-CELL ENGAGER ANTIBODY WITH A SINGLE CHAIN FC MOIETY THAT BINDS TO B CELL MATURATION ANTIGEN SURFACE RECEPTOR AND CD3

IMMUNOGLOBULIN SCFV-SCFV, ANTI-(HOMO SAPIENS TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17 (B-CELL MATURATION PROTEIN, CD269 ANTIGEN)) TNR17 AND ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN, CD3E ANTIGEN)) CD3E; MONOCLONAL ANTIBODY SINGLE CHAIN; BISPECIFIC; VARIABLE CHAINS ANTI-TNR17 (1- 243): (HOMO SAPIENS VH (IGHV1-46*01 (86%) (IGHD)-IGHJ4*01 (93%)) (8.8.14) (1-121)-TRIS(TETRAGLYCYLSERYL) LINKER (122-136), (HOMO SAPIENS VKAPPA (IGKV1-33*01 (92%) IGKJ1*01)) (6.3.9) (137-243),- SERYLTETRAGLYCYLSERYL LINKER (244-249); ANTI-CD3E (250-498): (VH (MUS MUSCULUS IGHV10-1*02 (92%)(IGHD)-IGHJ3*01 (87%)/HOMO SAPIENS IGHV3-73*01 (87%)-(IGHD)-IGHJ5*01)) (8.10.16) (250-374)- TRIS(TETRAGLYCYLSERYL) LINKER (375-389) V-LAMBDA (HOMO SAPIENS IGLV7-43*01 (85%) IGLJ3*02) (9.3.9) (390-498) PENTAHISTIDYLHISTIDINE (499-504), NONGLYCOSYLATED, PRODUCED IN CHO CELLS

IMMUNOGLOBULIN SCFV-SCFV, ANTI-(HOMO SAPIENSTNFRSF17 (TNF RECEPTOR SUPERFAMILY MEMBER 17, TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 17, B CELL MATURATION ANTIGEN, BCMA, BCM, TNFRSF13A, CD269)) AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON)), MONOCLONAL ANTIBODY SINGLE CHAIN, BISPECIFIC

IMMUNOGLOBULIN, ANTI-(HUMAN TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY PROTEIN TNFRSF17) (HUMAN MONOCLONAL BRA-KAN 1 SINGLE-CHAIN VARIABLE FRAGMENT VH1-(GGGGS)3-VL1) FUSION PROTEIN WITH PEPTIDE LINKER (GGGGS) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HUMAN MONOCLONAL BRA-KAN 1 SINGLE-CHAIN VARIABLE FRAGMENT VH2-(GGGGS)3-VL2) FUSION PROTEIN WITH HEXAHISTIDINE TAG

PACANALOTAMAB [INN]

PACANALOTAMAB [USAN]

PACANALOTAMAB [WHO-DD]